Cells for Cells (C4C), a pioneering regenerative medicine company based in Santiago, Chile, received news of the obtention of a new CORFO grant that will support the advancement of its biotech portfolio. The 100-million-pesos grant secured, named ‘Crea y Valida I+D+i – Reactívate,’ aims to support the design, testing, and validation of novel technological solutions. The grant is awarded by CORFO, the preeminent Chilean economic development agency linked to the Ministry of Economy, Development, and Tourism. Through tools and instruments such as the Crea y Valida grant, CORFO seeks to improve the country’s competitiveness and productive diversification by encouraging investment, innovation, and entrepreneurship.
The C4C project awarded consists of the same technology platform that obtained the 2020 Chilean National Innovation Award ( Premio Avonni). This patented biofabrication technique allows for the fast and scalable production of bioinspired and regenerative vascular implants. Through this approach, the team led by Dr. Juan Pablo Acevedo developed and validated Veintis™, a vessel-like graft conceived for patients with End-Stage Renal Disease and Peripheral Artery Disease. The new grant will help expand the applications of the biofabrication technology platform to other regenerative vascular implants such as patches for endarterectomy.
